Replies to post #112489 on Biotech Values

[jq1234]

What in the data released so far do you find to be interesting? It all looked pretty average for a mid-stage trial to me, except for the extraordinary results in the bones.

HCC and Ovarian data are very good compared to other drugs at this stage. If EXEL had enough resources, I am sure they would move forward on those two indications along with mHRPC.